Health Care & Life Sciences » Biotechnology | Arrowhead Pharmaceuticals Corp.

Arrowhead Pharmaceuticals Corp. | Mutual Funds

Mutual Funds that own Arrowhead Pharmaceuticals Corp.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Oppenheimer Global Opportunities Fund
7,800,000
8.86%
1,500,000
1.23%
03/31/2018
SPDR S&P Biotech ETF
2,626,274
2.98%
6,756
0.66%
09/06/2018
Vanguard Total Stock Market Index Fund
1,959,942
2.23%
0
0%
07/31/2018
iShares Russell 2000 ETF
1,821,857
2.06%
-972
0.06%
09/06/2018
Vanguard Extended Market Index Fund
1,157,075
1.32%
11,532
0.02%
07/31/2018
iShares Nasdaq Biotechnology ETF
1,011,001
1.14%
-13,230
0.15%
09/06/2018
iShares Russell 2000 Growth ETF
836,110
0.95%
0
0.11%
09/06/2018
PowerShares Dynamic Biotechnology & Genome Portfolio
835,882
0.95%
0
3.43%
09/05/2018
Fidelity Select Biotechnology Portfolio
810,201
0.92%
810,201
0.13%
07/31/2018
PowerShares DWA Healthcare Momentum Portfolio
484,465
0.55%
23,070
2.31%
09/05/2018

About Arrowhead Pharmaceuticals

View Profile
Address
225 South Lake Avenue
Pasadena California 91101
United States
Employees -
Website http://www.arrowheadpharma.com
Updated 07/08/2019
Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline includes clinical programs in chronic hepatitis B virus and partner based programs in obesity and oncology. The company was founded by R.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.